Usefulness of plasma B-type natriuretic peptide as a prognostic marker of cardiac function in senile systemic amyloidosis and in familial amyloidotic polyneuropathy

References

• Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011;29:1924–33
   PubMed Web of Science ®Google Scholar
• Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160–84
   PubMed Web of Science ®Google Scholar
• Westermark P, Bergstrom J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 2003;10:48–54
   PubMed Web of Science ®Google Scholar
• Cornwell GG III, Murdoch WL, Kyle RA, Westermark P, Pitkanen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 1983;75:618–23
   PubMed Web of Science ®Google Scholar
• Pitkanen P, Westermark P, Cornwell GG III. Senile systemic amyloidosis. Am J Pathol 1984;117:391–9
   PubMed Web of Science ®Google Scholar
• Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, Thibodeau SN. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996;101:395–400
   PubMed Web of Science ®Google Scholar
• Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425–9
   PubMed Web of Science ®Google Scholar
• Ueda M, Horibata Y, Shono M, Misumi Y, Oshima T, Su Y, Tasaki M, et al. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol 2011;24:1533–44
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78:74–82
   PubMed Web of Science ®Google Scholar
• Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440–5
   PubMed Web of Science ®Google Scholar
• Suhr OB, Anan I, Backman C, Karlsson A, Lindqvist P, Mörner S, Waldenström A. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008;263:294–301
   PubMed Web of Science ®Google Scholar
• Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047–60
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786–91
   PubMed Web of Science ®Google Scholar
• Ando Y, Ueda M. Diagnosis and therapeutic approaches to transthyretin amyloidosis. Curr Med Chem 2012;19:2312–23
   PubMed Web of Science ®Google Scholar
• Omori T, Tome Y, Imamura C, Fusegawa H. A difference between the analyzer which became clear for examination of brain natriuretic peptide (BNP). J Clin Lab Med 2011;55:928–32
   Google Scholar
• Suzuki S, Yoshimura M, Nakayama M, Mizuno Y, Harada E, Ito T, Nakamura S, et al. Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation 2004;110:1387–91
   PubMedGoogle Scholar
• Mukoyama M, Nakao K, Obata K, Jougasaki M, Yoshimura M, Morita E, Hosoda K, et al. Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun 1991;180:431–6
   PubMed Web of Science ®Google Scholar
• Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, Sundsfjord JA, Dickstein K. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963–9
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, Ohnishi M, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999;20:1799–807
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509–16
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9–13
   PubMed Web of Science ®Google Scholar
• Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, Gardetto N, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595–601
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997;30:1527–33
   PubMed Web of Science ®Google Scholar
• Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 2000;102:1788–94
   PubMed Web of Science ®Google Scholar